SN

Sridevi Narra

Active Director Director DIN 08619463
DIN 08619463 First appointment Nov 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2019
Shareholding value •••• Premium profile

About Sridevi Narra

Data last updated:

Sridevi Narra is a Director at Kpn Bio Pharma Private Limited (since 2019). The company operates in Pharma. Kpn Bio Pharma Private Limited reported revenue of ₹37.1 Lakh (FY 2022).

DIN 08619463
Primary Designation Director
Industry Pharma
First Appointment 22 Nov 2019
Oldest Company Age 6 yrs
Largest company Kpn Bio Pharma Private Limited · ₹37.1 Lakh (FY 2022)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Kpn Bio Pharma Private Limited U24304TG2019PTC137048
Director22 Nov 20192019₹37.1 Lakh (FY 2022)Active

Board colleagues of Sridevi Narra

Directorship timeline

Open interactive timeline →
Kpn Bio Pharma Private Limited
Premium access

Shareholding and investment profile for Sridevi Narra

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sridevi Narra

Sridevi Narra currently holds 1 directorship: Kpn Bio Pharma Private Limited (Director, since 22 Nov 2019, revenue ₹37.1 Lakh (FY 2022)).

Sridevi Narra was first appointed on 22 Nov 2019 as Director at Kpn Bio Pharma Private Limited.

The current boards of Sridevi Narra's companies include Krishna Prasad Narra (Kpn Bio Pharma Private Limited), Satyavardhan Reddy Komalla (Kpn Bio Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available